 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...1819202122232425262728...235236» |
- | Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, Trial completion date, Trial primary completion date, Metastases: Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer (clinicaltrials.gov) - Apr 18, 2024
P2, N=77, Active, not recruiting, Sponsor: Seoul National University Hospital
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- || Review, Journal: The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma. (Pubmed Central) - Apr 18, 2024
Neoadjuvant therapy, particularly FOLFIRINOX and gemcitabine-based regimens, is gaining favor for its potential to improve resectability rates and achieving microscopically negative margins (R0) in borderline resectable cases, marked by intricate arterial or venous involvement...Rates of curative resection are comparable, despite neoadjuvant therapy being a primary recommendation in borderline resectable cases and employed more often than upfront resection. Upfront resection may offer improved resection rates by intention-to-treat, which can provide more patients with paths to curative resection.
- || irinotecan / Generic mfg.
PK/PD data, Journal: Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin. (Pubmed Central) - Apr 18, 2024
Patients were treated with IP irinotecan every 2?weeks in combination with systemic FOLFOX-bevacizumab...Irinotecan is converted intraperitoneal to SN-38 by carboxylesterases and the plasma bioavailability of irinotecan is low. This model will be used for the further clinical development of IP irinotecan by providing dosing strategies.
- | Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment change: Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (clinicaltrials.gov) - Apr 18, 2024
P2, N=71, Recruiting, Sponsor: University of Wisconsin, Madison
This model will be used for the further clinical development of IP irinotecan by providing dosing strategies. N=110 --> 71
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, Trial completion date, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Apr 18, 2024
P1/2, N=31, Completed, Sponsor: Mayo Clinic
N=110 --> 71 Active, not recruiting --> Completed | Trial completion date: May 2024 --> Oct 2023
- | New P1/2 trial: FD-IMPACT: Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (clinicaltrials.gov) - Apr 17, 2024
P1/2, N=117, Not yet recruiting, Sponsor: Fudan University
- || MK-1084 / Merck (MSD)
Enrollment change, Monotherapy: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) - Apr 17, 2024
P1, N=830, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Completed | Trial completion date: May 2024 --> Oct 2023 N=450 --> 830
- | leucovorin calcium / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Apr 17, 2024
P2, N=56, Active, not recruiting, Sponsor: Southwest Autism Research & Resource Center
N=450 --> 830 Recruiting --> Active, not recruiting | N=134 --> 56 | Trial primary completion date: Jan 2025 --> Apr 2024
- | Keytruda (pembrolizumab) / Merck (MSD)
Phase classification, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Apr 17, 2024
P1/2, N=31, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=134 --> 56 | Trial primary completion date: Jan 2025 --> Apr 2024 Phase classification: P1b/2 --> P1/2
- || 5-fluorouracil / Generic mfg.
P2 data, Journal: Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study. (Pubmed Central) - Apr 16, 2024
P2/3
This has led to a successive multicentre phase III randomized trial investigating oncological benefit (EUDRA-CT 2023-506194-35-00). Current trial registration number: clinicaltrials.gov (NCT04552093).
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3. (Pubmed Central) - Apr 15, 2024
A high abundance of Desulfovibrio in the intestines indicates poor therapeutic outcomes for postoperative neoadjuvant FOLFOX chemotherapy in CRC. Desulfovibrio drives the manifestation of METTL3 in CRC, promoting resistance to FOLFOX chemotherapy by increasing the concentration of SAM.
- | Cyramza (ramucirumab) / Eli Lilly
Clinical Trial,Phase II, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. (Pubmed Central) - Apr 15, 2024
Medical records of patients with aGEC enrolled in the randomized phase II AIO-STO-0417 trial after treatment failure to first-line FOLFOX plus nivolumab and ipilimumab were retrospectively analyzed...Patients with CPS ?1 in the RAM group showed better tumor control (ORR 25% vs 10%) and improved survival (total OS 11.5 vs 8.0?months; second-line OS 6.5 vs 3.9?months; PFS 4.5 vs 1.6?months) compared to the control. Prior exposure to first-line FOLFOX plus dual checkpoint inhibition followed by RAM plus chemotherapy shows favorable response and survival rates especially in patients with initial response and positive PD-L1 expression and has the potential to advance the treatment paradigm in aGEC.
- || bemarituzumab (AMG 552) / Amgen
P2 data, Journal, Metastases: Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. (Pubmed Central) - Apr 15, 2024
P2, P3
Efficacy was more pronounced with FGFR2b overexpression in???10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626).
- | Tyvyt (sintilimab) / Eli Lilly
New P2 trial, Metastases: Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Apr 14, 2024
P2, N=40, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Accelerating Evidence Generation and Time to Insight With Clinical AI () - Apr 14, 2024 - Abstract #ISPOR2024ISPOR_2510;
To be useful for evidence generation, clinical AI must be able to reason over real-world data with physician-like intelligence. This session will: Explore how to evaluate clinical-specific reasoning capacity in AI & suitability for clinical applications Share data on how clinical AI-enabled analytics compare to unassisted analytics Delve into AI explainability and controlling hallucinations
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Clinical Trial,Phase II, Journal, Metastases: Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID). (Pubmed Central) - Apr 13, 2024
This session will: Explore how to evaluate clinical-specific reasoning capacity in AI & suitability for clinical applications Share data on how clinical AI-enabled analytics compare to unassisted analytics Delve into AI explainability and controlling hallucinations Our novel treatment strategy delivered acceptable survival outcomes and reduced severe dermatologic toxicities.
- || Tecentriq (atezolizumab) / Roche
P1/2 data, Journal: Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study. (Pubmed Central) - Apr 13, 2024
P2
This single-center phase I/II trial evaluated the safety, toxicity, and efficacy of neoadjuvant atezolizumab with oxaliplatin and 5-fluorouracil (modified FOLFOX) followed by esophagectomy followed by atezolizumab...Although modified FOLFOX plus atezolizumab did not achieve the expected pathCR, an acceptable safety profile was observed. Our results support the continued development of a more refined strategy (neoadjuvant chemotherapy plus perioperative immunotherapy/targeted agents) with molecular/immune profiling in parallel.
- | 5-fluorouracil / Generic mfg.
Journal: Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT. (Pubmed Central) - Apr 13, 2024
However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting.
- | Trial primary completion date, Surgery, Metastases: NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - Apr 11, 2024
P2, N=60, Recruiting, Sponsor: OHSU Knight Cancer Institute
Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting. Trial primary completion date: Apr 2024 --> Apr 2025
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Metastases: CONKO-007: Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (clinicaltrials.gov) - Apr 11, 2024
P3, N=830, Completed, Sponsor: University of Erlangen-N
Trial primary completion date: Apr 2024 --> Apr 2025 Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Nov 2023
- | Avastin (bevacizumab) / Roche
Biomarker, Trial completion date, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Apr 11, 2024
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Nov 2023 Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
- ||| AMG 193 / Amgen
New P1 trial: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Apr 11, 2024
P1, N=282, Not yet recruiting, Sponsor: Amgen
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Preoperative common hepatic artery embolization for pancreatic tail surgery () - Apr 10, 2024 - Abstract #ECIO2024ECIO_540;
Colonoscopy was performed with biopsy of adenocarcinoma and it was decided to perform colostomy and start treatment with FOLFIRINOX (6 cycles)...3).Pre-surgical vascular embolization is a valuable tool to establish collaterals to maintain the flow in organs which will not be resected. Vascular occluders are an excellent tool, and can be complemented with other embolizing agents.
- albumin-bound paclitaxel / Generic mfg.
Minimally invasive intratumoral holmium-166 microsphere implantation in patients with pancreatic ductal adenocarcinoma () - Apr 10, 2024 - Abstract #ECIO2024ECIO_517;
P=N/A
Primary endpoints are feasibility, assessed by post-procedural SPECT, and safety, assessed by continuous adverse event monitoring (CTCAE v5.0). For exploratory endpoints, ECOG score, Quality of Life questionnaires (EQ-5D-5L, EORTC QLQ-C30), pain scales, and laboratory examination focused on pancreatic, liver, immune, and renal function are performed at baseline and at every outpatient visit, and tumor response is assessed by RECIST after 16 weeks.
- ||| Enlituo (cetuximab biosimilar) / Mabpharm Limited, Sorrento
Trial completion date, Metastases: CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 10, 2024
P3, N=520, Active, not recruiting, Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
For exploratory endpoints, ECOG score, Quality of Life questionnaires (EQ-5D-5L, EORTC QLQ-C30), pain scales, and laboratory examination focused on pancreatic, liver, immune, and renal function are performed at baseline and at every outpatient visit, and tumor response is assessed by RECIST after 16 weeks. Trial completion date: Jun 2023 --> Jun 2024
- ||| Opdivo (nivolumab) / BMS
Enrollment change, Trial completion date, Trial primary completion date: CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) - Apr 10, 2024
P2, N=1500, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jun 2023 --> Jun 2024 N=800 --> 1500 | Trial completion date: Aug 2025 --> Aug 2029 | Trial primary completion date: Aug 2025 --> Aug 2029
- | Neurapeg (pegteograstim) / Green Cross Cell, Neulapeg (pegfilgrastim biosimilar) / GC Biopharma
New P2 trial, Metastases: Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX (clinicaltrials.gov) - Apr 8, 2024
P2, N=78, Active, not recruiting, Sponsor: Yonsei University
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Review, Journal, Metastases: Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. (Pubmed Central) - Apr 8, 2024
N=800 --> 1500 | Trial completion date: Aug 2025 --> Aug 2029 | Trial primary completion date: Aug 2025 --> Aug 2029 Liposomal irinotecan (ONIVYDE
- | Journal, HEOR, BRCA Biomarker, PARP Biomarker, BRCA Companion diagnostic, PARP Companion diagnostic, Cost-effectiveness, Cost effectiveness, Metastases: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer. (Pubmed Central) - Apr 8, 2024
Olaparib is not a cost-effective maintenance treatment option. Companion diagnostics are an equally important cost driver as the drug itself.
- | 5-fluorouracil / Generic mfg.
Journal: Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma (Pubmed Central) - Apr 8, 2024
There were no statistically significant differences in various adverse reactions between the two groups after HAIC treatment (all P>0.05). Patients with HBsAg-positive unresectable ICC are more likely to benefit from HAIC treatment.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, BRCA Biomarker, PARP Biomarker: A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX. (Pubmed Central) - Apr 8, 2024
Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associated with treatment and prevention of central nervous system metastases in long-term survivors of pancreatic cancer.
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 8, 2024
P2, N=80, Recruiting, Sponsor: Children's Oncology Group
The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associated with treatment and prevention of central nervous system metastases in long-term survivors of pancreatic cancer. Active, not recruiting --> Recruiting
- | Enrollment closed, Trial completion date, Trial primary completion date: PASS-01: Pancreatic Adenocarcinoma Signature Stratification for Treatment (clinicaltrials.gov) - Apr 8, 2024
P2, N=150, Active, not recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Jan 2025
- ||| TTX-030 / AbbVie, Trishula Therap
Trial completion, Metastases: ELTIVATE: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov) - Apr 8, 2024
P1, N=185, Completed, Sponsor: Trishula Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Jan 2025 Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Trial primary completion date: NOM-ERA: Non-Operative Management and Early Response Assessment in Rectal Cancer (clinicaltrials.gov) - Apr 8, 2024
P=N/A, N=63, Active, not recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Sep 2024
- |||| Solucin (177Lu-edotreotide) / ITM Isotopen Technologien Munchen
Trial completion date, Trial primary completion date, Patient reported outcomes: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (clinicaltrials.gov) - Apr 7, 2024
P3, N=202, Recruiting, Sponsor: ITM Solucin GmbH
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Sep 2024 Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Jun 2027
- | leucovorin calcium / Generic mfg.
Journal: British Oncology Pharmacy Association Delphi consensus guidelines: Co-infusion of trometamol-containing calcium folinate (Leucovorin) with systemic anti-cancer treatments. (Pubmed Central) - Apr 5, 2024
The Delphi process concluded after the fourth round, consolidating the findings and recommendations from the multidisciplinary team. Twelve recommendations for safe practice have been made.
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 5, 2024
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | New trial: PDAC-LIV: Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX (clinicaltrials.gov) - Apr 5, 2024
P=N/A, N=15, Recruiting, Sponsor: Laval University
- || Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Apr 4, 2024
P2, N=75, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Twelve recommendations for safe practice have been made. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- || P2 data, Journal: ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial. (Pubmed Central) - Apr 4, 2024
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 No abstract available
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial suspension, Trial primary completion date: Organ Preservation in Early Rectal Cancer Patients (clinicaltrials.gov) - Apr 4, 2024
P2, N=19, Suspended, Sponsor: Fox Chase Cancer Center
No abstract available Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Mar 2025
- | Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Mismatch repair, Tumor mutational burden: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - Apr 4, 2024
P3, N=700, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Mar 2025 Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
- | veliparib (ABT-888) / AbbVie
Trial completion date: S1513: FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 4, 2024
P2, N=123, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
Phase classification, Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=0, Withdrawn, Sponsor: NantPharma, LLC
Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025 Phase classification: P1b/2 --> P1/2 | N=64 --> 0 | Trial completion date: Dec 2024 --> Dec 2023 | Suspended --> Withdrawn | Trial primary completion date: Dec 2024 --> Dec 2023
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Clinical, Journal, Metastases: FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial. (Pubmed Central) - Apr 4, 2024
P2
Combination of immune checkpoint inhibitors with FOLFIRI in second-line treatment for advanced gastric/GEJ adenocarcinoma showed an acceptable safety profile but antitumor activity only in a subgroup of patients. ClinicalTrials.gov Identifier: NCT03959293.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Metastases: Naples prognostic score may predict overall survival in metastatic pancreatic cancer. (Pubmed Central) - Apr 3, 2024
ClinicalTrials.gov Identifier: NCT03959293. NPS may be a useful prognostic marker for the prediction of OS in metastatic PC patients receiving systemic chemotherapy.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Metastases: Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomes. (Pubmed Central) - Apr 3, 2024
Locally advanced rectal cancers with high-risk characteristics are a niche group of cancers with less-than-optimal outcomes post standard neoadjuvant strategies. mFOLFIRINOX appears to be well tolerated and enables TME in a significant proportion of these patients.
- |||||||| Opdivo (nivolumab) / BMS, botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
New P3 trial, Checkpoint inhibition, Tumor mutational burden, IO biomarker: CIME: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (clinicaltrials.gov) - Apr 3, 2024
P3, N=124, Not yet recruiting, Sponsor: Centre Leon Berard
- || AiRuiKa (camrelizumab) / HLB Bio Group, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Combination therapy: NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study (clinicaltrials.gov) - Apr 3, 2024
P2, N=40, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences